{
  "retracted": false,
  "timestamp": 1489968000000,
  "updates": [
    {
      "timestamp": 1585384758542,
      "identifier": {
        "doi": "10.1080/09546634.2017.1307464"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1080/09546634.2017.1294727"
  },
  "publisher": "Informa UK Limited",
  "title": "Correction to: Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75â€“89 response: results from two phase 3 studies of secukinumab"
}
